Pulmonx Corporation provided earnings guidance for the full year 2023. The company continues to expect revenue for the full year 2023 to be in the range of $63 million to $65 million.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
6.14 USD | -1.29% |
|
+6.41% | -51.84% |
Jun. 24 | Pulmonx Corporation(NasdaqGS:LUNG) dropped from S&P Healthcare Equipment Select Industry Index | CI |
Jun. 04 | Lake Street Initiates Pulmonx With Buy Rating, $12 Price Target | MT |
![Consensus](/images/consensus_flch.gif)
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-51.84% | 241M | |
+75.69% | 12.57B | |
+9.83% | 6.96B | |
-30.67% | 6.92B | |
+8.94% | 5.24B | |
-19.62% | 4.6B | |
+15.21% | 4.02B | |
-21.91% | 3.77B | |
-29.17% | 2.67B | |
+25.39% | 2.05B |
- Stock Market
- Equities
- LUNG Stock
- News Pulmonx Corporation
- Pulmonx Corporation Provides Earnings Guidance for the Full Year 2023